Skip to main
LIVN

Livanova (LIVN) Stock Forecast & Price Target

Livanova (LIVN) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 38%
Buy 50%
Hold 13%
Sell 0%
Strong Sell 0%

Bulls say

LivaNova has demonstrated strong growth, with sales increasing by 29% to $803 million for the year 2024, and management projecting an optimistic sales range of $940 million to $955 million for the upcoming periods. The company is expected to benefit from improved market share of its aura6000 product, with a potential increase from 2.4% in 2027 to 4.2% in 2029 under a Bear Case scenario, and even more favorable projections suggesting growth to 14.9% in the Bull Case. With around half of its revenue originating from the US market and a well-defined focus on its medical-device portfolio, LivaNova's strategic positioning supports a promising financial outlook.

Bears say

LivaNova's financial outlook appears unfavorable, primarily due to anticipated revenue growth decelerating to low single digits, which is attributed to ongoing challenges in its Neuromodulation and Cardiovascular segments. Additionally, the firm faces operational margin contraction and below-consensus earnings, further exacerbating its financial position. Risks associated with obtaining FDA approval for new products, coupled with slower-than-expected growth in both Neuromodulation and Cardiopulmonary sectors, heighten concerns regarding the company's profitability and market performance moving forward.

Livanova (LIVN) has been analyzed by 8 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 50% recommend Buy, 13% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Livanova and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Livanova (LIVN) Forecast

Analysts have given Livanova (LIVN) a Buy based on their latest research and market trends.

According to 8 analysts, Livanova (LIVN) has a Buy consensus rating as of Jan 13, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $67.38, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $67.38, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Livanova (LIVN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.